Lupus Journal

Overview

publication venue for

• Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman. 2013
• Extensive lymphadenopathy as the first clinical manifestation in systemic lupus erythematosus. 2000
• Sustained depression of B cell counts in lupus nephritis after treatment with rituximab and/or belimumab is associated with fewer disease flares. 2024
• Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")..  31. 2022
• COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION). 2021
• Impact of the first wave of the COVID-19 pandemic on systemic lupus erythematosus patients: Results from a multi-center prospective cohort. 2021
• 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome..  30. 2021
• A prospective study of reproductive factors in relation to risk of systemic lupus erythematosus among black women..  30. 2020
• Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. 2020
• Dietary patterns and risk of systemic lupus erythematosus in women..  29. 2019
• Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus..  27. 2018
• Bleeding complications and antithrombotic treatment in 264 pregnancies in antiphospholipid syndrome..  27. 2018
• Feasibility of Patient-Reported Outcomes Measurement Information System (PROMIS®) computerized adaptive tests in systemic lupus erythematosus outpatients..  27. 2018
• Long-term survival of kidney grafts in lupus nephritis: a Mexican cohort..  27. 2018
• Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease..  27. 2017
• Incidence of systemic lupus erythematosus in a population-based cohort using revised 1997 American College of Rheumatology and the 2012 Systemic Lupus International Collaborating Clinics classification criteria..  26. 2016
• The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus..  25. 2016
• Short-term patient-centered nutrition counseling impacts weight and nutrient intake in patients with systemic lupus erythematosus..  24. 2015
• Systemic lupus erythematosus is not a risk factor for poor outcomes after total hip and total knee arthroplasty..  24. 2015
• Effects of obesity on health-related quality of life in juvenile-onset systemic lupus erythematosus..  24. 2014
• Social capital: a novel platform for understanding social determinants of health in systemic lupus erythematosus..  24. 2014
• A new trick for an ancient drug: quinine dissociates antiphospholipid immune complexes..  24. 2014
• Anti-C1q antibodies in systemic lupus erythematosus..  24. 2014
• Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus..  23. 2014
• A surge in anti-dsDNA titer predicts a severe lupus flare within six months..  23. 2013
• Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I..  22. 2013
• Site differences in mild cognitive dysfunction (MCD) among patients with systemic lupus erythematosus (SLE)..  22. 2013
• A pilot study of office-based spirometry in patients with systemic lupus erythematosus..  21. 2012
• Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice..  21. 2012
• Association of the PTPN22 R620W polymorphism with increased risk for SLE in the genetically homogeneous population of Crete..  20. 2011
• 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010..  20. 2011
• Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions..  20. 2011
• Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations..  20. 2011
• Perceptions and measurements of physical activity in patients with systemic lupus erythematosus..  20. 2010
• Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information?.  19. 2009
• Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies..  18. 2009
• A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus..  18. 2009
• Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults..  18. 2009
• Do children with lupus have fewer male siblings?.  17. 2008
• Relationship of quality of life and physical function measures with disease activity in children with systemic lupus erythematosus..  14. 2005
• Quality of life in paediatric lupus..  13. 2004
• On being a Kunkel acolyte..  12. 2003
• Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome..  11. 2002
• Practice patterns of antiphospholipid syndrome at a tertiary teaching hospital in Lebanon..  11. 2002
• Reporting consistency in systemic lupus erythematosus patients: how reliable are patient histories?.  11. 2002
• FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients..  10. 2001
• Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study..  9. 2000
• Antiphospholipid antibody: future developments..  3. 1994
• Antiphospholipid antibodies differ in aPL cofactor requirement..  1. 1992
• Belimumab in primary antiphospholipid syndrome..  26. 2016
• Simple screening tool for assessing attention deficit in pediatric lupus..  25. 2015
• Lupus anticoagulant--hypoprothrombinemia syndrome and pregnancy..  10. 2001
• Elevated procalcitonin levels in a severe lupus flare without infection. 2016
• Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. 2003
• Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. 2003
• Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. 2003
• Treatment of pregnant patients with antiphospholipid syndrome. 2003
• Grand rounds from international lupus centres. 1997
• Images of lupus: diving for pearls..  9. 2000
• Why do patients with antiphospholipid antibody clot?.  6. 1997
• Does lupus flare during pregnancy?.  2. 1993
• The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 2015
• The interferon-alpha signature of systemic lupus erythematosus. 2010
• Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? 2010
• New developments in lupus-associated antiphospholipid syndrome. 2008
• The innate immune system in SLE: type I interferons and dendritic cells. 2008
• Quality of life in children with systemic lupus erythematosus: a review. 2007
• Systemic lupus erythematosus in children: current and emerging therapies. 2007
• Cardiac involvement in the antiphospholipid syndrome. 2005
• Studies of autologous T cell activation in the Kunkel laboratory. 2003
• Significance of aPL IgG subclasses. 1996
• Role of transforming growth factor beta (TGF beta) in systemic autoimmunity. 1993
• Risk of livedo with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis. 2022
• The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 2010
• Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. 2008
• Pathogenic role of antiphospholipid antibodies. 2008

Identity

ISO Abbreviation

• Lupus

Linking ISSN

• 0961-2033

International Standard Serial Number (ISSN)

• 0961-2033

Electronic International Standard Serial Number (EISSN)

• 1477-0962